All posts by imreal

Embark Behavioral Health Moves Support Office to Vibrant Chandler Mixed-Use Development


News Image

Our new space was intentionally designed to be a purposeful celebration of our culture and values. The feel is a cheerful one representing the hope our programs provide struggling families, and the joy and healing we ultimately look to create.

Embark Behavioral Health, a leading network of mental health treatment programs for youths and their families, recently moved its support office to a 24,000-square-foot office space in Chandler, Arizona. The company hired interior architecture firm PHX Design One to implement the vision it had for the office: a colorful space that mimics the warm welcome that Embark’s dozens of treatment programs provide families across the country.

Located inside the 250,000-square-foot Chandler Viridian building, near multiple dining and shopping options and Loops 101 and 202, the new office was selected for ease of access for teammates who live across the Valley. The location is also ideal given Embark is hiring in Phoenix.

The new space houses teammates in departments including finance, strategic planning, marketing, IT, and human resources. These departments exist to support and serve Embark’s mental health treatment programs across the country, which is why the Chandler location is called the support office. This service-driven culture also led to the office’s recent Arizona’s 2022 Top Workplaces award.

“Our new space was intentionally designed to be a purposeful celebration of our culture and values,” said Alex Stavros, CEO of Embark Behavioral Health. “The feel is a cheerful one representing the hope our programs provide struggling families, and the joy and healing we ultimately look to create.”

The New Space: A Closer Look

Bright pops of color in the paint, wall signage showcasing the company’s culture, and furniture pieces were integrated into the office design to help resemble Embark’s growing mental health care programs. Bright yellow, orange, blue, and green colors line the walls, with large screens playing client testimonials, highlights of Embark’s therapy programs, and inspiring messages congratulating employees on milestones and welcoming new hires. Multiple lounge areas, complete with couches and ottomans, offer seating spaces where employees and visitors can relax, connect with each other, and enjoy a view of the East Valley.

The open floor plan also includes a full-service kitchen with a coffee bar, a snack bar, and a variety of beverages, all complimentary for Embark employees and visitors.

The new office space has 43 private offices as well as six conference rooms. The conference rooms are separated from the rest of the space by partially frosted glass, giving them a bright, airy, cheerful look.

“Embark’s office design was very much driven by the company’s core purpose, which is to create joy and heal generations,” said Avalyn Zizzo, senior designer at PHX Design One. “Embark wanted potential visitors and teammates to feel an immediate sense of belonging once they entered the space. The color palette used throughout, including in the vibrant accents, matches Embark’s company logo, and the oak wood tones add warmth to the space. This project is a shining example of expressing a company’s brand, culture, and vision in its space.”

Additional Company Milestones

In addition to moving to a new support office, other Embark milestones this year include:


  • Opening new insurance-reimbursed short-term residential and outpatient clinic locations across the country, including California, Colorado, Maryland, Georgia, and Virginia.
  • Launching the Embark Behavioral Health Foundation with a mission to raise awareness of the youth mental health crisis, end the stigma around mental illness, and drive more access to high-quality services. The foundation will also provide a scholarship fund to help adolescents, young adults, and their families participating in mental health services pay for private pay programs, insurance co-pays, premiums, and general fees.
  • Debuting two monthly podcasts that provide expert interviews, advice, and tips on how to navigate mental health issues facing teens and young adults. “Roadmap to Joy” and “Embark Sessions” are available on the Embark website, Apple Podcasts, Spotify, and Google Podcasts.

To learn more, visit https://www.embarkbh.com/careers/. For more information about Embark Behavioral Health, visit http://www.embarkbh.com.

ABOUT EMBARK BEHAVIORAL HEALTH

Embark Behavioral Health is a leading network of outpatient centers and residential programs offering premier mental health treatment for preteens, teens, and young adults. Dedicated to its mission of reversing the trends of teen and young adult anxiety, depression, and suicide by 2028, Embark offers a robust continuum of care with different levels of service and programming; has a deep legacy of over 25 years serving youth; works with families to adjust treatment in real time to improve results; treats the entire family using an evidence-based approach; and offers the highest levels of quality care and safety standards. For more information about Embark or its treatment programs, including virtual counseling, intensive outpatient programs (IOPs), therapeutic day treatment programs, also known as partial hospitalization programs (PHPs), short-term residential treatment, wilderness therapy, and long-term residential treatment, visit http://www.embarkbh.com.

Share article on social media or email:

Advances in Precision Motion and Imaging Clinical Trial Endpoints Collection for Parkinson’s Disease, Upcoming Webinar Hosted by Xtalks


The speakers will share clinical examples illustrating the selection and use of appropriate imaging studies and wearable sensors technology to capture performance outcome clinical outcome assessment (PerfO COA) in Parkinson’s disease and related central nervous system conditions.

Register now to reserve your seat for this multidisciplinary virtual roundtable on advances in clinical trial endpoints collection for Parkinson’s disease.

During this roundtable, a panel of clinicians and scientists will review advancements in imaging modalities and the expansion of wearable sensors for instrumented performance outcome, and the collection of digital clinical trial endpoints for Parkinson’s disease trials. Examples will include how these approaches generate richer data and clinically meaningful outcomes in use cases to evaluate parameters such as disease progression and intervention efficacy. The featured speakers will discuss practical applications of precision motion sensor-based solutions to generate real-world data on patient functional mobility, and how it can influence patient’s perception of Quality of Life & Activities of Daily Living impact.

In this webinar, the speakers will share clinical examples illustrating the selection and use of appropriate imaging studies and wearable sensors technology to capture performance outcome clinical outcome assessment (PerfO COA) in Parkinson’s disease and related central nervous system conditions.

Join the speakers as they share their experiences and insights on the key aspects of selection and analysis in clinical trial endpoints, including recent US Food and Drug Administration Digital Health Technology (FDA DHT) guidance and Clinical consortia collaboration on digital outcome measures, data quality management and the expanding role of wearable technology devices in decentralized and hybrid trials.

Join Kristen Sowalsky, DC, PhD, Director Clinical Science and Consulting, Clario; Dr. Fay Horak, PT, PhD, Chief Scientist, Consulting, Clario; Martina Mancini, MS, PhD, PD KOL, Consulting, Clario; Diane Stephenson, PhD, Critical Path Institute; and Madhura Ingalhalikar, PhD, MRI Scientist, Neuro Medical Affairs, Clario, for the live webinar on Friday, September 23, 2022, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Advances in Precision Motion and Imaging Clinical Trial Endpoints Collection for Parkinson’s Disease.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Complex Knee Surgeon, Robert LaPrade, MD, PhD, Ranks Among the Top Orthopedic Researchers in the World as h-index Surpasses 100


Robert LaPrade, MD, PhD joins the list of most highly cited researchers.

Robert LaPrade, MD, PhD joins the list of most highly cited researchers.

Achieving the elite status of an h-index over 100 is rare air that only the best of the best ever breathes.

Complex knee surgeon and research clinician scientist, Robert LaPrade, MD, PhD, joins the list of most highly cited researchers (h-index => 100 according to his public profile in the Google Scholar Citations database). A high h-index value signifies Dr. LaPrade’s leadership in the Orthopedic field and underscores the degree to which his research has advanced and inspired the work of peer scientists. An h-index of 100 indicates that Dr. LaPrade has published 100 papers that have each received 100 or more citations 100 or more times. When a paper is frequently cited, it demonstrates that other researchers and orthopedists are using those results to test and prove new theories that subsequently provide fresh discoveries. This process is how research serves as the basis for continuously advancing the field of orthopedics and improving outcomes.

Currently practicing at Twin Cities Orthopedics in Edina, Minnesota, Dr. LaPrade is best known for his research in the fields of orthopedic surgery, sports medicine, and complex knee injuries that includes: anterior cruciate ligament (ACL), posterior cruciate ligament (PCL), posterolateral knee, medial collateral ligament (MCL), anterolateral ligament (ALL), tibial slope, stress radiographs, meniscus, meniscus root, and cartilage.

According to Alan Getgood, MD, orthopedic surgeon, and clinician scientist specializing in complex knee reconstruction at Fowler Kennedy, London, Ontario, “Dr. LaPrade’s vast body of work has shaped how many surgeons perform knee surgery. This has had a significant impact on countless numbers of patients, in terms of how they have been treated in the past and, for others, how they will be treated in the future. This truly leaves a remarkable legacy.”

Dr. LaPrade’s most cited works include:

  • The Anatomy of the Medial Part of the Knee. (812 citations)
  • Motion of the Shoulder Complex During Multiplanar Humeral Elevation (679 citations)
  • The Posterolateral Attachments of the Knee a Qualitative and Quantitative Morphologic Analysis of the Fibular Collateral Ligament, Popliteus Tendon, Popliteofibular Ligament, and Lateral Gastrocnemius Tendon (524 citations)

“Congratulations to Dr. LaPrade! He is one of the most thoughtful and prolific researchers in orthopedic sports medicine of our generation whose research has impacted thousands of students, colleagues and improved the care for countless patients with complex knee injuries. Achieving the elite status of an h-index over 100 is rare air that only the best of the best ever breathes,” said Mark Hutchinson MD, Professor & Director of Sports Medicine, University of Illinois College of Medicine.

———-

About the h-index:

The h-index is a metric used for measuring and comparing the overall scientific productivity of an individual scientist. The advantage of the h-index is that it combines productivity (number of papers produced) and impact (number of citations) in a single number. So, both productivity and impact are required for a high h-index; neither a few highly cited papers nor a long list of papers with only a handful of citations will yield a high h-index. The h-index indicates that scientific researchers who have 20 years of research with a 20-h-index is good and 40 is outstanding. An h-index over 100 is truly exceptional, placing Dr. LaPrade in a very small and elite group of approximately 3200 individuals who have achieved this status worldwide. The group includes distinguished researchers ranging from Nobel Laureates to leading engineers and scientists in every discipline. Sigmund Freud, for example, is on this list with an h-index of about 280.

About Dr. LaPrade:

As one of the world’s most celebrated complex knee surgeons and clinician scientists, Dr. LaPrade has published more than 625 peer-reviewed scientific manuscripts and has over 35,000 citations and 125 book chapters, and has given over 1000 professional presentations, symposia, grand rounds, and instructional course lectures. He has received many awards for his research, including the OREF Clinical Research Award, considered a Nobel Prize of Orthopedics and his research team has been awarded the AOSSM Excellence in Research Award three times since 2009, The Achilles Research Award from ISAKOS two times and the Cabaud Award by the AOSSM. In addition, he is overall the most published author in the top cited orthopedic journal, the American Journal of Sports Medicine (AJSM), with over 190 publications in AJSM alone. He is also the sole author of the only comprehensive textbook on posterolateral knee injuries and has been the editor for several sports medicine textbooks. He is recognized as a pioneer in knee research, with many referrals from international and nationally recognized physicians due to his successful patient outcomes and his development of more effective anatomic-based surgical techniques for the reconstruction of complex knee injuries.

Share article on social media or email:

Crisis Prevention Institute Data Show Student Trauma is a Paramount Focus for Educators this School Year


News Image

“When CPI talks about managing student behavior, it goes much deeper than student management. It’s about building the character and independence of students and a student’s ability to stay rational rather than emotional when presented with challenges,” said Dr. Kevin Mabie.

As the back-to-school season is in full swing, students and teachers are carrying unaddressed anxiety and stress from the previous year, as well as the normal back-to-school jitters, that will affect their behaviors and performance in and out of the classroom. Crisis Prevention Institute (CPI), the world leader in de-escalation and workplace violence prevention, surveyed educators nationwide to gauge their critical concerns and focus for the 2022-23 school year. CPI found that student trauma, teacher stress, mental health issues and increased anxiety are top areas of concern.

“This data amplifies an already pressing problem impacting schools nationwide,” said Susan Driscoll, President of CPI. “Research has shown that by 16, more than two-thirds of teens will have experienced a potentially traumatic event. Now, the pandemic has left feelings of chronic unpredictability and isolation in its wake. If the environment feels unsafe, it can change the way we think and our capacity to think. Therefore, schools must intentionally cultivate environments of connection and safety.”

Survey findings include:

  • 22% of respondents said that student trauma, mental health issues and increased anxiety are schools’ primary focus
  • 18% of educators polled said that they would be focusing their efforts on disruptive behaviors in the classroom
  • Staffing shortages will be the focus for 15% of educators surveyed

These findings by CPI come on the heels of a recent Education Week survey that found more than four out of every ten educators said at least one teacher in their district had been physically assaulted or attacked by a student in the past year. However, before the release of that data, it was clear that educators were under unprecedented strain. The National Education Association estimates that 55% of teachers nationwide are planning to leave the profession sooner than expected due to the impact of the pandemic.

“Educator trauma, anxiety and stress have turnover at unprecedented rates,” said Dr. Kevin Mabie, Global Professional Instructor at CPI and former educator. “As trauma and anxiety continue to filter into the classroom, educators see a significant increase in behavioral changes from their students. As a result, educators are challenged with not only addressing those behaviors but also creating a culture of safety for the students witnessing them.”

CPI training can help alleviate secondary traumatic stress/vicarious trauma in educators by:

  • Providing confidence and emotional-regulation skills to use when managing trauma in students
  • Creating a collaborative team approach to address challenging behaviors
  • Increasing job satisfaction and performance

Incorporating trauma-informed teaching helps educators:

  • Enhance social and emotional safety in both students and colleagues
  • Prevent vicarious trauma
  • Improve student outcomes

“When CPI talks about managing student behavior, it goes much deeper than student management. It’s about building the character and independence of students, a student’s ability to stay rational rather than emotional, and to be innovative and persistent when presented with challenges,” said Dr. Mabie. “CPI acknowledges that no two students are the same; strategies that work for one student might not work for another. As an educator with years of experience, I appreciate this. CPI doesn’t try to give me a singular philosophy that would guide my future classroom management; instead, it equips me with various tools I can use when interacting with students of any age, helping me get the best out of their unique and diverse personalities.”

Federal COVID relief funding is available to support CPI’s essential training for educators. The grant requires that at least 20% of these funds be used to address learning loss through evidence-based interventions that respond to students’ academic, social and emotional needs. CPI training for educators meets this requirement.

To schedule a free consultation, visit this link.

To learn more about CPI, visit crisisprevention.com

About Crisis Prevention Institute:

Crisis Prevention Institute is a world-leading training organization specializing in the safe management of disruptive and assaultive behavior. The Company’s Nonviolent Crisis Intervention® training program is embraced worldwide by organizations committed to providing quality care and services in a respectful, safe environment. The strategies taught in the Nonviolent Crisis Intervention® training program provide staff members with an effective framework for decision making and problem solving to prevent, de-escalate, and safely respond to disruptive or assaultive behavior. The philosophy relating to Care, Welfare, Safety, and SecuritySM expands throughout the continuum of interventions that are necessary when working toward reduction or elimination of restraint use.

For more information: https://www.crisisprevention.com

Share article on social media or email:

RoosterBio and MBL Beijing Biotech Partner to Accelerate Advanced Therapy Manufacturing in China


“RoosterBio’s engineered media products are creating transformative impact for cell and exosome therapy developers all over the world.” – Tim Kelly, CEO, RoosterBio

RoosterBio, Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services, today announced it has entered an exclusive distributor partnership with MBL Beijing Biotech (MBL Beijing), a JSR Life Sciences Company supplying industry-leading products to support life sciences. Under the agreement, RoosterBio’s expansion media, exosome collection media, bioreactor media, and genetic engineering media will be sold and distributed by MBL Beijing, making them readily accessible for the first time to MSC and exosome therapy developers in China.

“RoosterBio’s engineered media products are creating transformative impact for cell and exosome therapy developers all over the world,” said Tim Kelly, CEO of RoosterBio. “One of our key objectives in 2022 is to expand global access to our best-in-class products and services, particularly in Europe and Asia. Some of the most exciting R&D in the MSC and exosome space is being conducted in China, so we have sought to partner with an industry leader in that region. MBL Beijing quickly emerged as the clear choice for this collaboration based on their outstanding track record of supporting researchers throughout China to deliver not just high-quality products, but comprehensive solutions to drug development challenges. We are thrilled to partner with the MBL Beijing team to accelerate the development of cell and exosome products and help deliver these innovative therapies to patients in China.”

In addition to product distribution, the agreement creates an access path to RoosterBio’s process development and analytical services, which have helped advanced therapy developers throughout the world accelerate leading candidates into the clinic. These services combined with media solutions offers therapy developers a complete solution, addressing upstream expansion of hMSC’s in 2D flasks or 3D bioreactors, optimized conditions for exosome collection, and downstream processes to achieve purity, yield, and potency of the final formulated drug product.

“China has a strong focus on MSC and exosome therapies and we were impressed with RoosterBio’s products and services designed to support this market”, said Tamao Kaku, Managing Director of MBL Beijing. “After evaluating the current solutions available, we determined that drug developers in China will greatly benefit from the RoosterBio technology platform and product portfolio. We are pleased to have the opportunity to support our cell and exosome therapy developers by offering this industry-leading solution.”

MBL Beijing will start accepting and fulfilling RoosterBio orders in September 2022.

About RoosterBio

RoosterBio accelerates human mesenchymal stem/stromal cell (hMSC) and extracellular vesicle (EV) product and process development to fuel the rapid implementation of scalable advanced therapies. Our high-quality hMSCs, bioprocess media, genetic engineering tools, and EV production solutions are paired with expert bioprocessing knowledge to progress therapeutic developers from concept to first-in-human testing and commercial manufacturing at reduced cost and increased productivity. With optimized, scalable processes, Type 2 Drug Master Files, and cGMP products, we have enabled therapeutic programs to traverse their path to clinical translation in under 1 year. RoosterBio is driven by clients’ success and creating a world where safe and effective advanced therapies are rapidly developed and widely available on a global scale.

http://www.roosterbio.com

LinkedIn: RoosterBio

About MBL Beijing

MBL Beijing Biotech Co., Ltd (called MBL Beijing for short) is a JSR Life Sciences company. The company was founded in 2005 and is wholly owned by MBL (Medical & Biological Laboratories Co., Ltd) in Japan. MBL Beijing provides both JSR and MBL products, such as magnetic microparticles, latex particles, blocking agents, protein A chromatography resins, biomarker antibodies, diagnostic raw materials, MHC tetramer, organoid, in-vivo functional grade antibodies, cell culture media, and etc. Based on the support of their parent companies` professional technical team, MBL Beijing can adapt to constantly changing market demands and provide integrated corporation programs for customers. The company is dedicated to providing high-quality products and solutions to advance life science research, IVD manufacture, pharmaceutical, and biotechnology companies.

http://www.mbl-chinawide.cn

WeChat: MBLchina

Share article on social media or email:

RADX Announces the Catalyst-GPU Family of COTS PXIe/CPCIe Modules with NVIDIA Quadro GPUs


RADX Catalyst-GPU COTS PXIe/CPCIe Modules with NVIDIA GPUs

“With Catalyst-GPUs, PXIe users, for the first time, can directly benefit from the remarkable power of inexpensive, easy-to-program (in MATLAB, Python or C/C++), NVIDIA GPUs for their signal processing and AI applications,” said Ross Q. Smith, RADX Co-Founder and CEO.

RADX® Technologies, Inc. (“RADX”), today at IEEE AUTOTESTON 2022, announced the Catalyst-GPU™ Family of COTS, low-cost, PXIe/CPCIe GPU Modules. Catalyst-GPUs are the first COTS products that bring the cost-effective, easy-to-program, high-performance compute acceleration and advanced graphics capabilities of NVIDIA® Quadro® T600 and T1000 GPUs to the PXIe/CPCIe platform – the fastest growing platform for Modular Test & Measurement (T&M) and Electronic Warfare (EW) applications.

With comprehensive support for MATLAB™, Python, and C/C++, combined with support for virtually all popular computing frameworks, Catalyst-GPUs are easy-to-program for both Windows and Linux operating environments. Catalyst-GPUs feature multi-teraflop (TFLOP) level performance, which is ideal for accelerating Signal Processing applications. In addition, Catalyst-GPUs are ideal for Machine Learning (ML) and Deep Learning (DL) applications, which are becoming increasingly important for AI-based signal classification and geolocation, semiconductor and PCB testing, failure prediction, failure analysis, and other important missions.

INDUSTRY LEADING PERFORMANCE – WHERE DATA IS ACQUIRED

The Catalyst-GPU T1000 model supports up to 2.5 FP32 TFLOPs. Until now, this level of compute acceleration has not been available in PXIe/CPCIe systems. With Catalyst-GPUs, users can now conduct fast and accurate analysis of acquired data directly in the PXIe/CPCIe systems where the data is acquired.

For example, in an NI PXIe-1092 Chassis with an NI PXIe-8881 Embedded Controller (Intel Xeon W-2245 8C/16T 3.9 GHz), running Windows 10 and MATLAB, the Catalyst-GPU T1000 delivers an average performance gain of 7.1x over the Embedded Controller on FP32 Fast Fourier Transforms (FFTs) ranging from 1k to 32M samples in length. Under Python, the Catalyst-GPU T1000 delivers an average performance gain of 19.2x.

On ML and DL AI Applications, the performance gains achievable by Catalyst-GPUs are also quite substantial. On the MATLAB FP32 Deep Learning Inference Benchmarks, the Catalyst-GPU T1000 delivers an average 18.4x performance gain over an Intel Xeon W-2245 8C/16T 3.9 GHz PXIe Embedded Controller.

“A key use case for Catalyst-GPUs is accelerating MATLAB applications in a convenient and cost-effective manner,” said Ross Q. Smith, RADX Co-founder and CEO. “MATLAB is extremely popular with T&M and EW R&D users and MATLAB’s intrinsic support for NVIDIA GPU acceleration means users can now speed up their signal processing and AI applications directly in their PXIe/CPCIe data acquisition systems – without having to transport gigabytes or terabytes of sensitive data to other analysis systems via ethernet or sneakernet, and without having to spend months porting their applications to other platforms.”

IMPROVED ACCURACY AND RBW FOR ENHANCED LPI SIGNAL PROCESSING

For signal processing applications, Catalyst-GPU supports arbitrary length FFT, PSD, Correlation, and other DSP algorithms. This capability enables accuracy and Resolution Bandwidths (RBWs) that are not practicable in non-GPU based systems. For example, in most FPGAs, the longest practical lengths for FFTs are typically 8k points (samples). However, in Catalyst-GPUs, 1M point and longer FFTs are practical, and, because of the GPU’s TFLOP performance capabilities, 1M FFTs may be executed in real-time or near-real-time, depending on the application. With longer FFTs, a signal’s true spectral composition becomes more apparent and actionable, and Low Probability of Intercept (LPI) signals become readily detectable and characterizable.

EASY-TO-PROGRAM VIA MATLAB, Python and C/C++

One of the most important aspects of Catalyst-GPUs is their ease-of-programming, which stems from their underlying NVIDIA GPUs that support programming via MATLAB™, Python and C/C++, which enables compute acceleration available via NVIDIA CUDA® and OpenCL®. This ease-of-programming has resulted in NVIDIA GPUs becoming the most popular compute accelerators in the world today – with literally millions of engineers, application developers and computer scientists using NVIDIA GPUs to accelerate their applications. Catalyst-GPUs support both Windows and Linux operating environments. In addition, Catalyst-GPUs support popular AI and other frameworks, including MATLAB™, TensorFlow, PyTorch, RAPIDS AI and RAPIDS cuSignal, to name a few.

“NI LabVIEW has efficient methods for calling Python, C/C++ and MATLAB libraries, including RADX’ own Transform-DSP libraries. This makes adding Catalyst-GPU acceleration to LabVIEW-based PXIe applications a snap,” said Matt Dennie, Director of Engineering and Certified LabVIEW Architect at Acquired Data Solutions (ADS). “Using this approach, we were able to greatly improve the performance and accuracy of one of our LabVIEW signal processing apps in days, versus the weeks or months it would take with other methods.”

ABOUT CATALYST-GPUs

Based on RADX’ patent-pending Catalyst-X™ design, Catalyst-GPU models available today include NVIDIA Quadro T600 and T1000 GPUs; and RADX plans to offer Tech Insertion options in the future, based on COTS GPU availability. Catalyst-GPUs support PCIe Gen 3 x8 interfaces for optimal performance and 4 x miniDP outputs for multi-monitor applications with resolutions up to 4k. The Catalyst-GPU T600 supports 4GB of GDDR6 memory, up to 1.7 FP32 TFLOPs and a Total Graphics Power (TGP) of 38W – suitable for operation in all NI and 3rd-party PXIe chassis. The Catalyst-GPU T1000 supports 8GB of GDDR6 memory, up to 2.5 FP32 TFLOPs and a TGP of 50W, which is optimized for deployment in NI PXIe-1092 and NI PXIe-1095 Chassis, both of which support 58W/Slot or 82W/Slot and PCIe G3 x8 interfaces, which are ideal for optimum GPU performance. For more info on Trifecta-GPUs, please visit http://www.radxtech.com/products/trifecta-gpu.

PRICING AND AVAILABILITY

Catalyst-GPU T600 and T1000 models have list prices of $2,999 and $3,499, respectively. Lead time for single unit orders is typically 30 days, starting in Q422. Catalyst-GPUs are BAA and TAA Compliant, manufactured in the USA, and are available on GSA via TestMart (https://tinyurl.com/muk72crx).

ABOUT RADX

Founded in 2011, RADX Technologies, Inc., is a high-tech small business that develops COTS, High Performance Computing (HPC) hardware and software products that enable advanced signal processing, data acquisition, and ML/DL AI inference applications for SDR and PXIe/CPCIe platforms and T&M and EW markets. As an NI Alliance Silver Partner, RADX focuses on products and solutions, including the Trifecta and Catalyst Family of PXIe/CPCIe Modules and Transform-X™ Software Examples that complement the NI PXIe and USRP product lines. RADX products are BAA / TAA compliant and are available on GSA from TestMart at https://tinyurl.com/muk72crx. RADX is headquartered in California with development locations in UT, NM, and India. For more info on RADX, please visit http://www.radxtech.com, email info@radxtech.com or call +1 (619) 677-1849 x1.

NOTES: RADX, the RADX logo, Trifecta-SSD, Trifecta-GPU, Catalyst-GPU and Catalyst-GbE are trademarks or registered trademarks that are the property of RADX Technologies, Inc. All other trademarks are the property of their respective owners. All specifications are thought to be accurate at the time of publication but are subject to change without notice. Catalyst-GPU benchmarks were conducted by RADX in July 2022 on an NI PXIe-1092 Gen 3 Chassis with an NI PXIe-8881 Embedded Controller running Windows 10.

Ingenovis Health’s General Counsel Honored with Denver Business Journal’s C-Suite Award


“Marc is an accomplished legal, healthcare and business professional who is highly deserving of this award,” said Ingenovis Health Chief Executive Officer Bart Valdez.

Ingenovis Health announces General Counsel Marc Bonora as a recipient of Denver Business Journal’s prestigious C-Suite Awards. Bonora will be honored at the Journal’s awards reception on Sept. 21.

The 2022 C-Suite Awards honor the CFOs, COOs, CMOs, CLOs, Regional Managing Partners and other senior executives throughout the metro Denver area who have demonstrated vital leadership and business acumen to guide their companies to success this year. Nominees were judged on individual and organizational accomplishments, community involvement, contributions to management and innovation within their fields, among other factors.

“Marc is an accomplished legal, healthcare and business professional who is highly deserving of this award,” said Ingenovis Health Chief Executive Officer Bart Valdez. “Marc has been an important member of the executive team through a time of unprecedented growth, guiding legal strategy and compliance through a transaction, merger and two acquisitions in 24 months. He continues to play a critical role in realizing Ingenovis’ vision through corporate compliance, protecting and defending the company legally, and leveraging his experiences with large, complex organizations on a broad array of business decisions.”

Bonora joined Ingenovis Health in early 2021, bringing more than 20 years of legal experience, including positions with Envision Healthcare, Vail Resorts and the U.S. Department of Justice. Throughout his career, he has used his experience and training to not only advance business interests, but also to help the underserved, ranging from volunteer work with the 9/11 Commission, to stopping human trafficking in Tennessee. Now in an Executive MBA at the University of Colorado – Denver, Marc brings many talents to the executive team.

At Ingenovis, Bonora is the first Chief Counsel for an organization that has more than doubled in size in less than two years. The company strives to build a home for healthcare talent, and Marc is a zealous advocate for that goal. Ingenovis provides opportunities to over 10,000 healthcare providers across the country at the six brands of Ingenovis Health, including Denver-based Fastaff and U.S. Nursing. Moreover, Bonora has a passion for ensuring diversity and inclusion at Ingenovis, where 67% of the workforce are women.

To learn more about Ingenovis Health, visit http://www.ingenovishealth.com.

About Ingenovis Health

Ingenovis Health is an ingenious new force in healthcare, combining the power of industry-leading workforce solutions providers and a technology-forward approach to advance the delivery of critical healthcare clinicians to systems nationwide. Brands in the portfolio include Trustaff Travel Nurses, Fastaff Travel Nursing, U.S. Nursing Corporation, CardioSolution, HealthCare Support, and VISTA Staffing Solutions. For more information, visit http://www.ingenovishealth.com.

Share article on social media or email:

empty tomb’s Latest The State of Church Giving Edition


Angus Maddision’s Millennial Analysis, Year 0-1998, Per Capita GDP, 1990$

U.S. per capita Gross Domestic Product grew over 2000% from 1820 to 1998 in constant 1990 dollars, according to economist Angus Maddison … Since 1998, U.S. per capita GDP has continued to grow … The church needs to dust off Jesus’ advice … to serve God rather than Money (Matthew 6:24) .

Fact: Church member giving declined in 2019, the year before the COVID pandemic took off, according to data published in empty tomb’s latest edition, The State of Church Giving through 2019: Serve God with Money At-Scale or Serve Money (January 2022).-

Fact: As giving to churches as a percent of income declined between 1968 and 2019, so did church membership as a percent of U.S. population.

Fact: Those in the U.S., including church members, are living in an age of affluence not seen during the previous 2,000 years, according to an analysis by economist Angus Maddison considered in the new book (see accompanying chart).

Solution: Churches need to recover their roots, putting mission before maintaining operations. In so doing, churches will be serving God rather than money.

Specific Giving and Membership Facts.

The first seven chapters of the book analyze different aspects of church giving and membership.

1. For a composite set of Protestant denominations, in 2019, the year before COVID hit, per member giving in current dollars, as well as in inflation-adjusted dollars and as a portion of income, was lower than the year before in 2018 (chapter 1).

2. In 2019, U.S. per capita after-tax, inflation-adjusted income had increased 171% compared to 1968. Yet, instead of increasing or even just maintaining the portion of income given to the church, per member giving as a percent of income decreased 35% from the 1968 base, from 3.02% to 1.95% (chapter 1).

3. In 2019, of the money that came into a congregation, 84% was spent on the church’s internal activities, and 16% was spent on the larger mission of the church. Those numbers indicate a turning inward, compared to 1968, when 79% was spent on the church’s internal activities, and 21% was spent on the larger mission of the church (chapter 1).

4. The declining trends are evident in both mainline and evangelical Protestant denominations (chapter 3).

5. For a data set of 11 major Protestant denominations, giving as a percent of income was lower in 2019 than in 1921 or 1933, the depth of the Great Depression (chapter 4).

6. A data set of 34 Protestant denominations, including some of the fastest growing in the U.S., and the Roman Catholic Church, represented 45% of the U.S. population in 1968 and 33% in 2019 (chapter 5).

What Is the Solution?

Chapter 8 explores a solution to these trends.

U.S. per capita Gross Domestic Product grew over 2000% from 1820 to 1998 in constant 1990 dollars, according to economist Angus Maddison’s analysis. Since 1998, U.S. per capita GDP has continued to grow.

In the face of this unprecedented affluence, the church needs to dust off Jesus’ advice from 2000 years ago and figure out what it means to serve God rather than Money (Matthew 6:24) in this new circumstance.

Relevant quotes from church leaders reflecting on Jesus’ teachings, including Augustine of Hippo, Martin Luther, and John Wesley, are presented in the book.

The new book suggests this accumulated wisdom points to a solution. The new affluence has encouraged an increasing focus on the comfort of current church members. The solution is recovering an outward focus on a scale made possible by this great affluence.

By its nature, Christianity is aspirational. If the church is not aspiring to a goal that is on a scale with the resources available and the need in the world, the church will wither.

The church can help others in desperate need, and do it in Jesus’ name, at a level never before possible. A side benefit of this recovered approach might be a revitalization of the church itself as people become interested in the churches’ larger purpose.

What Is the Potential for Good?

Chapters 6 and 8 document the financial potential of church members to impact global needs.

To make a shift from an internal to external emphasis, the book suggests, the church needs to focus on where the needs are the greatest. Global needs present a challenge on a par with the affluence flooding the U.S.

A specific need considered in chapter 8 is the more than 1 million children under age 5 dying each year from preventable causes. Using the still available distribution and communication systems of denominational channels, churches could embrace a vision of reducing these needless deaths.

Church members currently conduct all their activities on less than 2% of their incomes. If they donated another 6%, and focused on their global neighbors’ needs, these church members would have had an additional $454 billion in 2019 to apply to these needs.

Is that enough? The book cites a combined figure of $83.2 billion a year more that is needed for churches to address, in Jesus’ name, child deaths; Bible translation and workers for unengaged, unreached people groups; nutrition security; water-sanitation-hygiene basic services; and basic primary education availability.

The solution to the downward trends, then, is dependent not on the church’s ability to act, but rather, in light of these facts, whether the church chooses to use the power for good now at its command.

The new book, the 31st in the series, was published January 2022. It is available at Wipf and Stock Publishers, wipfandstock.com.

Miami-Based Clinical Trial Company First In U.S. To Run Trials For MM-120 (LSD D-TARTRATE)


News Image

Conducting the first trial of its kind in the nation puts our companies at the forefront of psychedelic pharmacological research.

Segal Trials, a privately held network of clinical research sites throughout South Florida, announced that its’ investigators and the site are the first in the United States to conduct a large, randomized clinical trial to investigate MM-120 (LSD D-tartrate), for the treatment of Generalized Anxiety Disorder (GAD). Segal Trials’ investigators administered the first dose of MM-120 to a study participant on August 24th at The Center for Psychedelic and Cannabis Research in Miami, FL.

Dr. Rishi Kakar, Medical Director and Chief Scientific Officer at Segal Trials, serves as a Principal Investigator for the MM-120 trial, which is a randomized, double-blind, parallel-group design study to evaluate the potential effectiveness of MM-120 in patients with GAD.

“MindMed’s compound has the potential to change the way clinicians treat GAD,” said Dr. Kakar. “Certainly, conducting the first trial of its kind in the nation puts our companies at the forefront of psychedelic pharmacological research.”

Dr. Kakar and his team will conduct the trial at Segal’s Center for Psychedelic and Cannabis Research, which was specifically built to create a structured inpatient environment that ensures patient safety and comfort.

About Generalized Anxiety Disorder (GAD)

GAD is a chronic, often debilitating mental health disorder that affects approximately 6% of U.S. adults in their lifetimes. Symptoms of GAD include excessive anxiety and worry that persists for over six months, which can lead to significant impairments in social, occupational and other functioning, according to the National Institute of Mental Health (NIMH). While there is substantial diagnostic overlap between GAD, Major Depressive Disorder (MDD) and other major mental health disorders, there has been very little innovation focused on the treatment of GAD in the past several decades due to the shift in focus from anxiety disorders like GAD toward depressive disorders like MDD, driven by the marketing of serotonin reuptake inhibitors starting in the 1990s.

About Segal Trials

Segal Trials, founded in 1998, is a privately held network of research sites throughout South Florida conducting Phase I-IV research trials that have led to 54 FDA-approved medications and devices. The company’s trials focus on psychiatry, neurology, addiction, insomnia, infectious diseases, vaccine development, and women’s health; and it runs trials in outpatient, inpatient, PSG, and residential care facility settings.

For more information about Segal Trials, or to schedule an interview, please contact Meieli Sawyer at msawyer@weinbachgroup.com.

About MindMed

MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. The company is developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.

MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.

For Media, email media@mindmed.co; for Investors, email ir@mindmed.co.

Share article on social media or email:

Axis Medical Staffing Makes Inc. 5000 List For Second Consecutive Year


Axis Medical Staffing

Axis Medical Staffing

Our growth is a direct reflection of the relationships we build throughout the organization. At the end of the day, we would not be in the position we are if not for the exceptional talents of our internal team and the heroic efforts of our travel nurses.

Axis Medical Staffing, a Seattle-based leader in nationwide healthcare staffing, has made the Inc. 5000 List of the fastest-growing private companies in America for the second year in a row. The company’s spot on the Inc. 5000 list is a testament to its commitment to quality and excellence in every aspect of its business. Axis Medical Staffing’s success has been driven by its innovative business model and commitment to providing high-quality medical staffing solutions.

The lnc. 5000 list recognizes the country’s top 5,000 private companies that have experienced the most revenue growth over the past three years and represents the most comprehensive look at the most important segment of the economy—America’s independent entrepreneurs. The Inc. 5000 list is one of the most prestigious honors in the business world and it recognizes the fastest growing private companies in the US based on revenue growth. Along with the Inc. 5000 award, Axis Medical Staffing was also ranked the #1 travel nursing agency in the nation for 2022 by BluePipes and Better Nurse, and the #2 travel nursing company by Highway Hypodermics.

Founded in 2004 by co-CEOs Ryan Skjonsberg and Adam McKinnon, Axis Medical Staffing provides healthcare staffing solutions with a focus on travel nurse contract assignments. In addition to earning its second-consecutive spot on the Inc. 5000 list, Axis Medical Staffing was also ranked #103 on Inc.’s Regional Pacific list. The company’s continued success “highlights the quality of our team, our nurses, as well as the stability and growth of the company,” says McKinnon.

Axis Medical Staffing’s revenue increased by 276 percent in the previous three years. The company’s growth has been driven by its commitment to providing quality medical staffing solutions for hospitals and other healthcare organizations nationwide. As the recipient of multiple industry awards, Axis Medical Staffing has received recognition for its commitment to both its clients and its contractors by consistently being named as one of the best travel nursing agencies in the country. “Our growth is a direct reflection of the relationships we build throughout the organization. At the end of the day, we would not be in the position we are if not for the exceptional talents of our internal team and the heroic efforts of our travel nurses,” said Skjonsberg.

The Inc. 5000 list began in 1982 as the Inc. 500 list of the fastest growing private companies across America. In 2007, it was expanded to include 5000 of the nation’s most successful private companies. Rankings are determined by overall revenue growth over a three-year period.

“The accomplishment of building one of the fastest-growing companies in the U.S., in light of recent economic roadblocks, cannot be overstated,” says Scott Omelianuk, editor-in-chief of Inc. “Inc. is thrilled to honor the companies that have established themselves through innovation, hard work, and rising to the challenges of today.”

About Inc.

Inc. is the most well-known, trustworthy name in business-focused media, which provides entrepreneurs with the necessary resources and community they need to build successful businesses. Across its wide variety of outlets, its award-winning multiplatform content reaches more than 50 million people each month. It has produced the Inc. 5000 list every year since 1982, which analyzes company data to recognize the fastest-growing privately held businesses in the United States. The Inc. 5000 Conference & Awards Ceremony takes place every year and showcases the phenomenal feats of these companies. Rankings on the Inc. 5000 are based on percent revenue growth from 2018 to 2021.

About Axis Medical Staffing

Axis Medical Staffing is a leading workforce management partner for some of the nation’s most respected healthcare organizations. A Joint Commission certified organization since 2007, Axis specializes in contract assignments for travel nurses and allied healthcare professionals. Visit https://www.axismedicalstaffing.com or call 888-299-2947. Axis Medical Staffing is located at 100 West Harrison Street, South Tower, Suite 550, Seattle, WA 98119.

Share article on social media or email: